Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
emcure
28 tablet
daclatasvir dihydrochloride
Keep in cold place
Delivering To:
Overview
Declacure 60 mg tablet is used for the treatment of chronic hepatitis C virus (HCV). It is an antiviral medication often used along with other medications. This medication lowers the viral dose of the hepatitis C virus (HCV) in the blood.
Hepatitis C
Chronic hepatitis C virus (HCV) infection
The human body reacts differently to Declacure 60mg tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Declacure 60mg tablet are mentioned below: Headache
Nausea
Unusual tiredness
Anemia
Insomnia
Dizziness
Shortness of breath
Irregular heartbeat
Chest pain
Fatigue Allergic reaction
Upset stomach
Trouble sleeping
Memory problems
Low blood sugar
Vomiting
Abdominal cramps
Swelling of the mouth, face, tongue, or throat
Take the dose of Declacure 60mg tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you.This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Declacure 60mg tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
An antiviral medication, Daclacure tablet, is used for the treatment of Hepatitis C virus (HCV) infection. It works by lowering the viral load from the blood; as a result, Infected individuals feel relief from the related symptoms of the chronic hepatitis C infection. Daclacure tablet causes a decrease in serum RNA levels of HCV by stopping the function of the nonstructural protein 5A (NS5A) protein in the replication complex. The effect of this medicine can be easily seen within 2 hours after its oral administration.
Alcohol
unsafe
It is advised not to consume alcohol with Daclacure 60mg Tablet because the medicine might interact with alcohol, causing harmful effects on the body of the infected individual. Consult your doctor for further information.
Pregnancy
consult your doctor
Do not take Daclacure 60mg Tablet without consulting the doctor. In case of pregnancy, taking Daclacure 60mg Tablet might be unsafe. According to some researchers, this medicine may be harmful to the developing baby.
Breast Feeding
consult your doctor
Breastfeeding mothers taking Daclacure 60mg Tablet are advised to consult the doctor first before taking this medicine. According to a few researchers, taking Daclacure 60mg Tablet is known to harm the developing baby, as this medicine can pass to the foetus through breast milk.
Driving
danger
It is advisable not to drive or operate heavy machinery, as one of the side effects of the medicine. It is advisable not to drive or operate heavy machinery after taking Daclacure 60mg Tablet, as you may feel dizzy.
Kidney
caution
Please share your medical history with the doctor before starting Daclacure 60mg Tablet. Do not take Daclacure 60mg Tablet without consulting a doctor, as it may worsen the health condition of the individual.
Liver
caution
Share your medical history with the doctor before starting the Daclacure 60mg Tablet. Do not take Daclacure 60mg Tablet without consulting a doctor, as it may worsen the health condition of the individual.
It is advisable not to miss a dose of Daclatasvir Dihydrochloride 60mg Tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.
During pregnancy, it is not safe to take Daclacure 60mg Tablet as it can cause harm to the unborn baby. Also, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.
Daclacure is an antiviral medication that is used in the treatment of chronic Hepatitis C virus.
Some common side effects are diarrhea, allergic reactions, nausea, anemia, insomnia, fatigue, chest pain, vomiting, etc.
Follow your doctor’s instructions about any restrictions on food and other activities
Daclacure 60mg Tablet works by lowering the load of the virus and removing Hepatitis C infection from the blood over time.
It is advised not to take alcohol while taking the Daclacure 60mg Tablet because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.
As soon as you remember, take the missed dose. unless it's time for your next dose. You should never take a double dose to make up for a missed one.
Please ask your doctor if you face this issue, as it may be linked to a lung problem.
Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. (2024). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 57(8):911-928.
Eley T, Garimella T, Li W, Bertz RJ. (2023). Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. Clin Pharmacokinet. 54(12):1205-22.
Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, Sautou V, Abergel A. (2025). Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 83(2):269-293.
Kiang TKL. (2024). Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 43(5):509-531.
Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW. (2023). Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 74(3):710-717.
De Bellis E, Donnarumma D, Zarrella A, Mazzeo SM, Pagano A, Manzo V, Mazza I, Sabbatino F, Corbi G, Pagliano P, Filippelli A, Conti V. (2024). Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know. Pharmaceutics. 17(1):31.
Priyanka PSSL, Varma DM, Immadisetti K, Rajesh R, Vidyasagar S, Guddattu V. (2023). Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications. Int J Risk Saf Med. 29(1-2):25-55.
emcure
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.